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The demonstration by Francis and Tillett (1) and others (2-5) that the type- 
specific polysaccharides of pneumococci are antigenic in man and induce the 
production of antibodies  in  humans  which  protect  mice  against  subsequent 
injection of virulent  organisms,  has  led  to  numerous attempts  to  use  these 
purified polysaccharides in  active immunization  (4,  6).  Since the  antipoly- 
saccharide in Type I antimeningococcal sera has also been found to be effective 
in protecting mice, the capacity of several preparations of Type I meningococcal 
polysaccharide to induce precipitin formation in human volunteers was studied. 
Use was made of the colorimetric micro method for the estimation of antibody 
developed by Heidelberger and MacPherson (7) and applied in a study of the 
antibody response accompanying convalescence from pneumonia  (8). 
Preparations of the specific polysaccharide of the Type I meningococcus have 
been made and characterized by Scherp and Rake (9).  Their materials, how- 
ever, were shown to contain at least 20 per cent of a  second substance which 
reacted with antimeningococcal sera  (10)  but was found not to remove pro- 
tective antibody (11).  A  sample of polysaccharide (preparation  18  (9))  was 
generously supplied  by  Dr.  H.  W.  Scherp  for use in  this investigation.  In 
addition, since both glacial acetic acid and barium hydroxide had been used in 
purifying their polysaccharide, several lots were prepared in which the use of 
these fairly drastic reagents was avoided.  The chemical and immunological 
properties of these materials were studied and it was found that, unlike prepara- 
tion 18,  they showed only a  slight zone in the quantitative precipitin reaction 
where both antigen and antibody could be detected in the supernatant.  No 
evidence 6f precipitin formation in humans was obtained with preparation 18, 
but in a few instances a small but significant antibody response to injection of 
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several  of  the  other  polysaccharides  was  obtained,  accompanied  in  three  in- 
stances by the presence of protective antibody  which was specifically removed 
by  absorption  with  the  same  polysaccharide  sample  used  in  immunization. 
Methods  and  Materials 
Prepa/ration of Polysoccharide--Freshly isolated lyophilized strains of Type I meningococci 
obtained from Drs. H. E. Alexander and J. J. Phair were transferred in  peptone blood broth 
and then into Difco tryptose phosphate broth or to the casein hydrolysate medium described 
by Mueller and Hinton (12) but prepared without agar.  The organisms were grown in 2-liter 
flasks, each containing 1 liter of medium, and incubated for 10 days at 37 °.  After the 1st day 
a pellicle was noted at the surface of the broth, and the flasks were shaken daily.  The cultures 
were killed by addition of 95 per cent phenol to a concentration of 0.5 per cent.  Contaminants 
were detected by examination of smears and by plating before addition  of phenol and any 
contaminated flasks were discarded.  The cell debris was removed in a  Sharples centrifuge 
and when casein hydrolysate medium was used, the starch was digested with saliva.  The 
broth was then concentrated to about one-tenth its original volume by nltrafiltration through 
alundum candles coated by dipping into a  4 per cent or 6.5 per cent parlodion solution in 
glacial acetic acid and then washed free of acid.  It was found that small amounts of serologi- 
cally active material passed through the 4 per cent membrane, but only traces could be de- 
tected after filtration through a 6.5 per cent membrane or through cellophane (of. 9).  In some 
instances the concentrated broth was then shaken with chloroform to remove protein (13), 
but it was found that complete removal of protein could not be effected. 
In the case of lot M5, the concentrated tryptose broth (original volume, 8 liters) was shaken 
with chloroform, centrifuged, and 2 volumes of ethyl alcohol were added to the aqueous phase. 
The precipitate was dissolved in dilute sodium acetate and an equal volume of alcohol added. 
After several reprecipitations in this manner, a product (M5A) was obtained which was sero- 
logically inactive and was discarded.  To the supernatant containing 2 volumes of alcohol 2 
more volumes were added to precipitate the polysaccharide (MSB).  M5B was redissolved 
in 80 ml. sodium acetate solution and precipitated with 2 volumes of alcohol.  This precipitate 
was centrifuged, dissolved, reprecipitated with 1 volume of alcohol, the precipitate discarded, 
and the polysaccharide fraction M5B then precipitated by addition of alcohol to 4 volumes. 
3 additional volumes of alcohol were added to the supernatants from the M5A reprecipitations 
and the precipitates were combined with M5B.  The combined precipitates were dissolved 
in 64 ml. water and an equal volume of saturated ammonium sulfate was added.  The pre- 
cipitate was centrifuged and the supernatant dialyzed overnight against running water in a 
cellophane sac.  Sodium acetate was added and the solution fractionally precipitated with 
alcohol into three fractions, MSB 1, MSB2, M5B3, by successive addition of 2, 3, and 4 volumes 
of alcohol respectively.  Each of these fractions was reprecipitated several times with alcohol, 
dissolved in water, and additional protein precipitated by addition of 2 volumes of saturated 
ammonium sulfate.  After centrifuging, each supernatant was dialyzed free from ammonia, 
sodium acetate added, and the polysaccharide fraction precipitated with redistilled alcohol, 
washed with alcohol, and dried, yielding 247,  106, and 17 mg. of each fraction respectively. 
With M6, 5 liters of tryptose broth were concentrated by ultrafiltratlon, shaken with chloro- 
form, and the fraction precipitable by 1 volume of alcohol was discarded.  The supernatant 
was divided into fractions M6B and M6C by addition of 2 and 4  volumes of alcohol respec- 
tively.  Each of these fractions was dissolved and the protein precipitated by addition of 2 vol- 
umes of  saturated ammonium sulfate and removed.  The supernatants were dialyzed free 
from ammonia and precipitated with alcohol.  M6B and M6C were recombined and dissolved 
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fuged off, the supernatauts dialyzed free from NI-I~4  , and the polysaccharide (M6C) precipi- 
tated with alcohol.  At this point its specific rotation was but +10  ° instead of +40  ° to 50  ° 
indicating considerable impurity and it was dissolved in about 5 ml. of water and a saturated 
solution of safranin  (9)  added until no more precipitation occurred.  The precipitate was 
centrifuged off and washed with saturated safranin solution and with alcohol.  It was then 
repeatedly dissolved in  20  per cent sodium acetate solution and precipitated with alcohol 
until free from safranin.  The final precipitation was carried out with redistilled alcohol,  the 
gummy precipitate washed several times with redistilled alcohol,  and dried.  Yield 48  rag. 
M8 was made from 22 liters of tryptose broth.  Mter concentration by ultraflltration and 
shaking with chloroform, the material precipitable by  1 volume of alcohol was discarded. 
MSB was obtained by precipitation with 2 volumes of alcohol and M8C by precipitation be- 
tween 2 and 3 volumes.  M8B  was repreclpitated twice with alcohol from sodium acetate 
solution, dissolved in about 5 ml.  water, and 5 ml. solution containing 100 mg. protamine 
added.  The white precipitate was centrifuged off, dissolved in 20 per cent sodium acetate 
solution,  and  reprecipitated with  alcohol several times.  It  was finally precipitated with 
redistilled alcohol and dried.  MSB protamine-precipitate,  yield 235 rag.  MSC was saturated 
with ammonium sulfate, the precipitate centrifuged off, and the supernatant dialyzed free from 
ammonia.  Sodium  acetate  was  added  and  the  material  precipitated with  alcohol.  The 
precipitate (266 rag.)  was dissolved in water dialyzed against saline phosphate pH 7.4 and 
examined in the Tisolius electrophoresis apparatus (14),  It showed two components and the 
fast component was separated in as high a yield as possible.  This polysaccharide component 
(M8CF)  was precipitated with alcohol and dried as described above--yield 59  mg.  The 
unseparated M8C from the middle of the U tube was precipitated with protamine as described 
for MSB--yield 12 mg. 
17 liters of casein hydrolysate broth (M9) were concentrated to about 1 liter by evaporation 
in large cellophane sacs in a stream of air from an electric fan and the polysaecharide precipi- 
tated by addition of 4 volumes of alcohol.  The precipitate was dissolved and shaken with 
chloroform, the chloroform layer centrifuged off, and the material precipitable by 1 volume 
of alcohol removed and discarded.  3 more volumes of alcohol was added to the supernatant. 
The precipitate was dissolved in dilute sodium acetate and separated into two fractions M9B1 
and M9B2  precipitable between 0-2  and 2-4 volumes of alcohol respectively.  M9B2 was 
dissolved in water and the solution saturated with ammonium sulfate; the precipitate was 
removed and the supernatant dialyzed free from ammonia.  Sodium acetate was added and 
the polysaccharide thrown down with alcohol.  It was dissolved in 20 per cent sodium acetate 
and 4 volumes of methyl alcohol were added, the precipitate removed, and 4 volumes of ethyl 
alcohol added  to  the  supernatant.  The  ethyl alcohol insoluble fraction was centrifuged, 
dissolved in 20 per cent sodium acetate, reprecipitated several times with alcohol, finally with 
redistilled alcohol, and dried.  Yield 40 rag. 
Some of the properties of the various Type I  polysaccharide fractions pre- 
pared as above are given in Table I, together with data for sample 18 prepared 
by Scherp and Rake (9).  The electrophoretic mobilities and relative concen- 
trations  of the components present are also included.  The optical rotation, 
phosphorus content, and electrophoretic patterns of the M5 fractions indicate 
that some of the polysaccharide is precipitated by 2 volumes of alcohol but that 
most of it comes down between 2 and 4 volumes with less impurity.  Fractional 
alcohol precipitation and ammonium sulfate precipitation at best yield products 
containing  about 50 per cent polysaccharide.  However, by treatment  with 
safranin, separation by electrophoresis,  or by removal of impurities by methyl 302  TYPF.-SPE~FIC POLYSACCHARIDE OF  TYPE I  MENINGOCOCCUS 
alcohol, products  with  chemical properties  approaching those  of  sample  18 
were  obtained.  Two  of  these,  M6C  and M8CF,  showed  but a  single com- 
ponent in electrophoresis as did preparation 18, and the mobility found for all 
three samples was the same.  The analytical data for M9B2  were closest to 
those of No.  18.  The ash and phosphorus values on the two samples of pro- 
TABLE  I 
Chemical and Physical Properties of Type I Meningococcal Polysacckaride 
Preparation No. 
M5BI 
M5B2 
MSB3 
M6C 
M8CF 
M9B2 
18 (Scherp)~ 
M8C protamine 
precipitate 
M8B protamine 
precipitate 
IhT* 
per cent 
5.2 
4.7 
6.7 
4.3 
5.6 
5.8 
4.20 
10.2 
12.1 
[o]: 
per cent  degrees 
1.4  +19.4 
5.4  +23.6 
6.5  +26.6 
7.1  +41.5 
7.3  +37 
9.2  +51 
8.93  +57 
5.9  +8 
5.7  +9 
Electrophoretic pattern 
Mobility 
at pH 7.4 
#  X  10-6 
--1.5 
--10.6 
--1.5 
--11.6 
--10.9 
--10.2 
--11.3 
* Calculated to the ash-free basis, except where no ash determinations are gaven. 
Taken from (9). 
Amount of 
component 
present 
per cent 
88 
12 
52 
48 
100 
100 
100 
tamine-precipitated polysaccharide as compared with  those  of M6C,  M8CF, 
and M9B2 indicate a polysaccharide content about 55 to 60 per cent. 
Reactions of Type I  Polysaccharides  with Homologous  Antimeningococcal 
Horse  Serum 
Solutions containing 0.02 to 0.10 rag. of polysaccharide were added in duplicate at 0°C. to 
1 ml. portions of Type I  antimeningococcal horse serum H1095, obtained from Dr.  Jules 
Freund of the New York City Department of Health Laboratories.  The solutions were mixed 
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chilled saline.  The washed precipitates were dissolved with a  few drops of N/10 NaOH  and 
analyzed  for  nitrogen  by  the  micro  Kjeldahl  method  as  described  by  Heidelberger  and 
Kendall (15).  The supernatants were tested for the presence of excess antibody or polysac- 
charide  by  addition  of  polysaccharide or  antiserum.  (For  a  summary  of  quantitative im- 
munochemical methods see reference  16.)  The results are given in Table II. 
M6C,  M8CF,  M8B  protamine precipitate and M9B2  all reacted similarly 
with antiserum, precipitating a maximum of about 0.34 rag. antibody N  from 
1 ml. of serum.  Sample 18, however, precipitated considerably more antibody 
N from 1 ml. of serum and its supernatants showed a broad range in which both 
antigen  and  antibody could be  detected.  The other  preparations  behaved 
TABLE  II 
Antibody N Precipitated from 1 rid. Type I Horse Antiserum 1095 by Varying Amounts of Type I 
Meningococcal Polysacckarides 
M6C 
~k  Supernatant 
Pol~-  "~o 
saccna-  ,~ 
ride 
added  Z  + 
Anti-  -v-~  C  o ~  body 
.~'- 
mg.  mg. 
0.02  0.248 +++  " 
0.04  0.3o0 4-(+)  ++ 
0.06  0.332--(--)  ++-4- 
o.o8  o.34o -(-)  ++++ 
0.10  0.342 --(--) 4-++-'}-  i 
oo 
rag. 
0.256: 
0.298 
o.34o! 
0.350 i 
0.3501 
M8CF 
Supernatant 
Ma+CF 
++ 
++ 
+ 
-(--) 
-(--) 
+ 
Anti- 
body 
++ 
++++ 
++++ 
+++'4- 
MSB Protamine pre- 
clpitated 
Supernatant 
+  + 
~.',~ 
m.  ~  .. 
++++  - 
++  - 
±(4-)  ++ 
-(--)  +++ 
-  ++++ 
M9B2 
Z 
m&. 
0.318 
0.406 
0.484 
0.534 
0.$94 
t.  tx 
Z 
oo  .t:l ,~ 
~g. 
0.194 
0.251 
0.329 
0.340 
0.337 
..K  Supcrnatant 
eL 
+ 
:~  +  Anti-  "~-v  M9B2  o ~  body 
mg. 
0.262 "4-(+)  +('4-) 
0.286 --(4-) ++++ 
o.312 -  (-) ++++ 
0.294 --(--) ++++ 
0.278 -- (--) '+++-1- 
18 (Seherp) 
Supcrnatanl 
+++ 
++4- 
+++ 
+++ 
+++ 
+ 
Anti- 
body 
+ 
++ 
+++ 
+++ 
+++ 
Readings in parentheses after centrifugafion. 
* Corrected for additional protamlne N  in precipitate. 
much more like a single substance, since their supernatants showed only a very 
narrow zone in  which both components were present  (7,  16).  As  would be 
expected  from its protamine content equivalent weights  of M8B  protamine 
precipitate were less effective in precipitating antibody N from the horse serum, 
but the same  amount of antibody was removed when excess polysaccharide 
was added.  M9B2 appears to be most effective in precipitating antibody, but 
the  maximum  amount  precipitated was  somewhat  low.  M5B2  and  M5B3 
precipitated more than 0.90 rag. of antibody N  from 1 ml. of H1095 indicating 
the presence  of other immunologically reactive materials. 
Immunization Studies with Type I Polysacckaride 
The ability of a  number of the polysaccharides to produce precipitins was 
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Immediately following an initial bleeding (designated by a zero subscript)  two iujections 
of polysaccharide in saline containing 0.01 per cent merthiolate were given intracutaneously 
or subcutaneously to each individual at 1 day intervals.  Blood samples were drawn 3, 6, and 
12 to 14 weeks following the injections.  Antibody response was measured using the quantita- 
tive micro precipitin method of Heidelberger and MacPherson (7), described in detail in (8) 
in which the complement is first removed by the specific precipitate formed when 0.04  mg. 
of egg albumin (Ea) N is added to each of several 4.5 ml. portions of the human serum sample 
containing 0.4 rag.  anti egg albumin N.  After standing 48 hours in the icebox,  0.01 to 0.02 
mg. of Type I  meningococcal polysaccharide is added to aliquot portions of the supernatant 
from the Ea-anti Ea precipitate.  The tubes were allowed to stand in the icebox for 1 week 
and were centrifuged in a refrigerated centrifuge and washed three times with chilled saline. 
The precipitates were dissolved with 1 drop of N/10 NaOH and analyzed for nitrogen by a 
modification of the Folin-Ciocalteau tyrosine method using as a standard a calibration curve 
TABLE III 
Antibody  Formation in  Individuals  In  ected u~th Type  I  Meningococcal Polysaccharide 
Subject No. 
28 
43 
47 
51§ 
Polysaccharide  Amount 
used  injected 
mg. 
MSB3  0.05 
M6C  0.10 
M8CF  0.20 
M8CF  0.20 
Antibody N  per 4 ml. serum* 
Before 
injection 
mg. 
0.001 
0.002 
0.004 
0.007 
3 wks. 
rag. 
0.009 
0.006 
0.008 
After injection 
6 wks. 
mg. 
0.009 
0.009 
0.012 
0.008 
12 to 14 wks. 
mg. 
0.013 
0.0115 
0.012 
* The same preparation used for immunization was used for antibody N  determinations. 
~: 3,  6,  and  12 weeks after two additional injections of 0.12  mg. M6C,  values of 0.015, 
0.012, and 0.012 mg. antibody N per 4 ml. serum were obtained. 
§ Previously injected with 0.10  mg. of another  crude preparation  and  showed a  slight 
antibody response (0.007 mg. Ab N per 4 mh serum) which was maintained. 
obtained with known amounts of human gamma globulin N.  Results are expressed in milli- 
grams antibody N per 4 ml. serum. 
A  group  of 22  volunteers received injections  of 0.01  and  0.04  rag.  of poly- 
sacchaxide  No.  18  (Scherp).  Half of these were injected subcutaneously,  the 
rest  intracutaneously.  No significant amounts  of precipitin  N  were found in 
serum drawn 3, 6, and 12 to 14 weeks after injection.  Eleven of these individ- 
uals  received a  second  course  of two  injections  of 0.05 and  0.20 mg.  of poly- 
saccharide  and serum drawn  at similar intervals also contained no measurable 
amounts  of antibody  N  when  tested with  samples  18 or M5B3. 
Nineteen  volunteers  were  given  injections  of  0.01  and  0.04  mg.  of crude 
polysaccharide  M5B3.  Only  one  of  these  19  showed  a  significant  antibody 
response 3 weeks later which was maintained for 12 weeks (No. 28, Table  III). 
Four of the other individuals showed amounts of precipitin N  of 0.008 to 0.009 ELVIN A. EABAT~ HILDA KAISER, AND HELEN  SIKORSKI  305 
rag. antibody N per 4 ml. serum in but a single serum sample  and all other in- 
dividuals showed no measurable antibody. 
A third group  of 14 individuals was given two injections  each of 0.10 nag. 
M8CF.  Half of these received the material as a protamine precipitate.  In 
addition 3 persons received two injections of 0.02 and 0.08 rag. of M6C and 2 
volunteers received two injections of 0.08 mg. M6C.  Only 2 of the individuals 
injected with either M8CF or M6C showed a definite and persistent antibody 
response  (No. 47, 43, Table III). 
In three of the four instances in which definite precipitin  formation resulted 
(Table III), mouse protection tests carried out by Dr. C. P. Miller's laboratory 
at the University of Chicago showed the presence  of mouse protective anti- 
bodies.  These antibodies were no longer present in the serum after removal 
of the antipolysaccharide.  No protective antibodies were found in three sam- 
pies of serum from an individual injected with preparation 18 (Scherp) who did 
not produce precipitins.  A 1:30 dilution of serum 43, drawn 12 weeks after 
the second series of injections, protected ]  of the inoculated mice against 1000 
~x.r.D. of Type I  meningococci, as did a  1:30 dilution of serum 47 drawn 12 
weeks after injection.  A  1:1.4 dilution of the  12  week sample  of serum 51 
protected ]  of the mice against 1000 x~.L.D.  After absorption of the Type I 
antibody with M5B3 or with M6C and M8CF,'no protective power remained 
in the supernatant. 
DISCUSSION 
The purification  of Type I  meningococcal polysaccharide  from autolyzed 
broth by methods which avoid the use of strong acid or alkali is attended with 
considerable difficulty.  Although small yields of relatively pure material have 
been obtained by fractional precipitation with alcohol and removal of protein 
with ammonium sulfate, followed by precipitation with safranin,  separation of 
impurities by electrophoresis or by methyl alcohol, as yet none of these methods 
has proved adequate when maximum recovery of polysaccharide  was desired. 
This is perhaps due to the tendency of the polysaccharide to combine with pro- 
tein and other substances  present because of its high phosphorus  content (i.e. 
acidic groups)  and to carry down other impurities in the course of the usual 
precipitations. 
The data in Table I show that the properties  of the various polysaccharides 
are in general similar to those reported by Scherp and Rake (9) in showing a 
high ash and phosphorous content and 4 to 5 per cent N.  The Scherp and Rake 
sample, No. 18, and M6C and M8CF showed but a single component in electro- 
phoresis with a mobility of about 11 at pH 7.4, indicating a large number of 
acidic groups on the polysaccharide.  Since preparation 18 was found by Scherp 
to contain 20 per cent of a serologically reactive impurity (10), which may have 
affected the analytical data, the true optical rotation, N, P, and ash contents 306  TYPE-SPECIFIC POLYSACCHARIDE  Ol  ~ TYPE I MENINGOCOCCUS 
of pure  polysaccharide may differ somewhat from the  given  values.  This 
might in  part  account for  the  variation in  the  analytical constants of the 
different  polysaccharides.  The  formation  of  an  insoluble  protamine-poly- 
saccharide compound which is soluble in sodium acetate may prove to be of 
considerable value  in  further purification studies.  For  many purposes  the 
protamine-polysaccharide complex may even prove to be as satisfactory as the 
polysaccharide itself. 
The  quantitative  precipitin  data  obtained  in  Table  II  indicate  that 
M6C, M8CF, M9B2 as well as the protamine-polysaccharide complex contain 
much smaller amounts of immunologically  reactive impurities than does sample 
18, since their supernatants showed but a very slight zone in which both antigen 
and antibody were present, whereas the 18 supernatants gave tests for both anti- 
gen and antibody over a very wide range (of. 10, 16, 17).  M6C, M8CF, M9B2, 
and M8B protamine precipitate all removed about the same maximum amount 
of  antibody nitrogen  from  the  serum.  Equal  amounts  of  the  protamine- 
polysaccharide complex  nitrogen were  somewhat  less  effective in  removing 
antibody as would be expected from their lower polysaccharide content.  From 
the immunological standpoint, therefore, it appears that these polysaccharide 
preparations are much closer than preparation 18 to being a single substance. 
The results of the immunization studies in human beings indicate that the 
Type I  meningococcal polysaccharide is a  very poor antigen compared with 
the pneumococcal type-specific polysaccharides.  No antibodies were obtained 
in 22 individuals inoculated with preparation 18 and only four definite responses 
resulted among 38 individuals immunized with M5B3, M6C, or M8CF.  Two 
of these four were immunized with the purified preparations M6C and M8CF. 
In the three instances tested, the production of precipitins after immunization 
was associated with the presence of Type I  antibodies capable of protecting 
mice.  These antibodies were specifically removed by absorption with poly- 
saccharide.  Whether these positive results indicate that the polysaccharide 
is weakly antigenic cannot be definitely established.  The recent demonstration 
(11)  that Type I  meningococci contain another type-specific antigen which is 
also associated with mouse protection, makes it conceivable that in these few 
instances antibody to this other antigen was formed.  It is quite possible that 
traces of this antigen could be present even in the purified polysaccharides 
SUMMARY 
1.  Methods for preparing small amounts of Type I  meningococcal polysac- 
charide which are electrophoretically homogeneous and contain only traces of 
other immunologically reactive material are given. 
2.  These polysaccharides are very poor antigens in man but in a small number 
of instances definite amounts of precipitin and protective antibody were formed. 
3.  The significance of these findings is discussed. ~.LVIN A.  KABAT, HILDA KAISER, AND ]KELEN SIKORSKI  307 
The authors are indebted to Dr. C. P. Miller and Dr. A. Z. Foster for the mouse  protection 
tests. 
BIBLIOGRAPHY 
1.  Francis, T., Jr., and Tillett, W. S., J. Exp. Med., 1930, 52, 573. 
2.  Francis, T., Jr., Proc. Soc. Exp. Biol. and Meal., 1934, 31, 493. 
3.  Finland, M., and Sutliff, W. D., J. Exp. Med., 1932, 65, 853; J. Immunol.,  1935, 
29, 285. 
4.  Felton, L. D., Jordon, C. E., Hesbacher, E. N., and Vaubel, E. K., Pub. Health. 
Rep., U. S. P. H. S., 1941, 56, 1041, and other papers. 
5.  Finland, M., and Brown, J. W., J. Clin. Inv., 1938, 17, 479. 
6.  Heidelberger, M., unpublished studies for the Pneumonia Commission. 
7.  Heidelberger,  M., and  MacPherson,  C.  F.  C.,  Science, 1943, 97, 405; 98,  63. 
8.  Heidelberger,  M., and Anderson, D. F., J. Clin. Inv., 1944, in press. 
9.  Scherp, H. W., and Rake, G., J. Exp. Med.,  1935, 61, 753. 
10.  Scherp, H. W., J. Immunol.,  1939, 87, 469. 
11.  Kabat, E. A., Miller,  C. P., Kaiser, H., and Foster, A. Z., J. Exp. Meal., 1944, 
in press. 
12.  MueUer, J. H., and Hinton, J., Proc. Soc. Exp. Biol. and Med.,  1941, 48, 330. 
13. Heidelberger,  M., Kendall, F. E., and Scherp, H. W., J..Exp. Med.,  1936, 64, 
559. 
14. Tiselius, A., Tr. Faraday Soc., 1937, 23, 524. 
15.  Heidelberger,  M., and Kendall, F. E., J. Exp. Meal., 1935, 61, 559. 
16.  Kabat, E. A., J. Immunol.,  1943, 47, 513. 
17.  Kendall, F. E., J. Clin. Inv., 1937, 16, 921. 